Press Release: Sanofi Provides Update on MOBILIZE Phase 3 Study of Riliprubart in Chronic Inflammatory Demyelinating Polyneuropathy

Why It Matters

Halting MOBILIZE underscores the challenges of developing complement‑targeted therapies for CIDP and signals that Sanofi’s pipeline may face delays, but the unchanged guidance reassures investors about broader financial stability.

Key Takeaways

• MOBILIZE phase 3 study halted after interim efficacy analysis
• No safety concerns identified for riliprubart in the trial
• Sanofi's 2026 financial guidance remains unchanged despite study termination
• Future evaluation will focus on VITALIZE phase 3 study in IVIg‑treated CIDP

Pulse Analysis

Chronic inflammatory demyelinating polyneuropathy (CIDP) remains a therapeutic blind spot despite existing immunoglobulin and corticosteroid options. Roughly 30% of patients do not respond to standard‑of‑care treatments, and many experience incomplete remission, driving demand for novel mechanisms that can halt demyelination. Sanofi’s riliprubart, an IgG4 monoclonal antibody that blocks activated C1s in the classical complement cascade, was designed to intercept the inflammatory cascade implicated in nerve damage, positioning it as a potentially disease‑modifying candidate in a market eager for alternatives.

The MOBILIZE phase 3 trial, enrolling CIDP patients who had failed conventional therapy, was terminated after an independent data monitoring committee concluded that the study was unlikely to achieve its primary efficacy endpoints. Importantly, the interim analysis reported no new safety concerns, suggesting that while the drug’s tolerability profile is acceptable, its therapeutic impact fell short of expectations. Sanofi emphasized that the study’s closure will not materially affect its 2026 earnings outlook, indicating that the company has insulated its financials from this setback and can continue to fund its broader R&D agenda without immediate fiscal strain.

Looking ahead, Sanofi will redirect focus to the VITALIZE phase 3 trial, which evaluates riliprubart in CIDP patients already receiving IVIg. Success in that cohort could still validate the complement‑inhibition strategy and salvage the asset’s commercial potential. For investors and industry observers, the episode highlights the high bar for efficacy in rare neurological disorders and the importance of diversified pipelines. Even as one trial ends, the continued pursuit of complement‑targeted therapies may reshape the CIDP treatment landscape, offering hope for patients who remain underserved by current options.